On October 9, 2026, the clinical trial registry listing for NCT05069038 was updated to reflect a status change for a study involving goserelin. The trial, titled "Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy," is a Phase 2 study. Its current status is listed as active, not recruiting. This designation indicates that the trial is ongoing but is no longer enrolling new participants. Goserelin is used in this study as part of an endocrine therapy regimen alongside palbociclib in a neoadjuvant setting. No results or outcome data have been reported as part of this update. The update reflects only a change in recruitment and operational status, not any findings related to safety or efficacy. Goserelin remains an approved compound, and this trial represents one of its ongoing investigational uses in combination with other therapies. Readers interested in additional background can consult the compound overview for more context on goserelin.
Goserelin Trial NCT05069038 Status Updated to Active, Not Recruiting
See the full goserelin overview
Source: https://clinicaltrials.gov/study/NCT05069038